Showing results (221-230 of 242) with videos related to
Sort By:
Pageof 25
British Journal of Cancer|May 20, 2004
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomographyH Barthel, H Wilson, D R Collingridge, et al.Current Medicinal Chemistry|June 9, 2011
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitorsS J Shuttleworth, F A Silva, A R L Cecil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.Cancer Research|August 1, 1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxiaE O Aboagye, R J Maxwell, A B Kelson, et al.Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.The British Journal of Radiology|October 1, 1986
A comparative study of Ro 03-8799: racemic mixture and enantiomersH F Newman, E P Dunphy, N M Bleehen, et al.British Journal of Cancer|October 1, 1985
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma)H Baillie-Johnson, P R Twentyman, N E Fox, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancerL R Kelland, V Smith, M Valenti, et al.Oncogene|August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.Pageof 25